何雅億 副主任医师，副教授
硕士招生类型：学术型；专业型
硕士招生专业：肿瘤学
博士招生类型：学术型；专业型
博士招生专业：肿瘤学
所在院系：附属肺科医院
联系方式：**@qq.com
课题组链接：
研究方向
主要任职
科研业绩

肺癌分子靶向治疗，免疫治疗，早期诊断及转移的临床及转化研究
Clinicaland Transformational Study of Lung Cancer Molecular Targeted Therapy,Immunotherapy, Early Diagnosis and Metastasis



中国临床肿瘤学会（CSCO）非小细胞肺癌专委会秘书，中国控制吸烟协会肺癌防治专委会委员， CSCO、ASCO、ESMO及IASLC会员。担任OncoTargets and Therapy、Medical Science Monitor等SCI杂志审稿人
Secretary of China Society of ClinicalOncology (CSCO) Non-small Cell Lung Cancer Committee, Member of Chinese LungCancer Prevention Committee of Smoking Control Association, Member of CSCO,ASCO, ESMO and IASLC. Reviewer of SCI magazines such as OncoTargets andTherapy, Medical Science Monitor, etc.



2015年获得国际肺癌研究协会（IASLC）中国****奖，至美国科罗拉多大学肿瘤系进行为期一年的访问****工作。2017年12月至2018年5月响应上海市卫计委号召，至云南东川开展援滇工作，获得“东川荣誉市民”称号。
2017年获得上海市浦江人才。2016年参与获得上海抗癌科技奖二等奖，2017年参与获得中国抗癌协会科技奖一等奖，2018年参与获得上海市科学技术奖一等奖。在临床工作的同时，主持并参与国家自然科学基金多项，以项目负责人的身份主持2018年CSCO齐鲁肿瘤研究基金课题一项，以项目负责人的身份完成上海市卫生局课题一项，以项目秘书身份参与完成上海申康医院发展中心慢性病综合防治项目，并获得同济大学及同济大学附属上海市肺科医院新人培育项目各一项。目前，参与完成上海市重中之重呼吸病学重点学科及重大疾病临床技能提升项目。
临床工作中，每年诊治患者2000余例，其中新诊肺癌患者600余例。每年完成肺穿刺300余例，气管镜200余例。在临床工作中进行肺癌转化相关研究，成果多次在美国临床肿瘤学会（ASCO）、欧洲临床肿瘤学会（ESMO）、世界肺癌大会（WCLC）等国际会议上进行口头交流及壁报展示，并获得2016年ESMO Travel Grant。参与多项肺癌靶向治疗、免疫治疗等相关的多中心、III期临床研究。目前共发表论文39篇，以第一作者/共第一作者身份发表论文25篇，涵盖了肺癌分子靶向治疗，免疫治疗及早期诊断等方面。以秘书身份参与2019年CSCO原发性肺癌诊疗指南及晚期非小细胞肺癌抗血管生成药物治疗的中国专家共识编写工作。以第一发明人身份申请国家实用新型专利六项。

In 2015, Dr. He won the ChineseScholar Award of the International Association for Lung Cancer Research (IASLC)and worked as a visiting scholar in the Department of Oncology, University ofColorado, USA for one year. From December 2017 to May 2018, in response to thecall of the Shanghai Municipal Health and Planning Commission, Dr. He went toDongchuan, Yunnan Province to work there, and won the title of "honorarycitizen of Dongchuan".
In 2017, Dr. He was awarded Pujiangtalents in Shanghai. In 2016, Dr. He won the second prize of ShanghaiAnti-cancer Science and Technology Award. In 2017, Dr. He won the first prizeof Chinese Anti-cancer Association Science and Technology Award. In 2018, Dr.He won the first prize of Shanghai Science and Technology Award. Dr. He alsoparticipated in many projects of the National Natural Science Foundation ofChina, Qilu Cancer Research Foundation of CSCO in 2018, completed one projectof Shanghai Health Bureau as project leader, and participated in the completionof Shanghai Dr. Henkang as project secretary. Dr. He finished the project ofcomprehensive prevention and treatment of chronic diseases in the HospitalDevelopment Center awarded to Tongji University and Shanghai Pulmonary Hospitalaffiliated to Tongji University. Dr. He finished the key subjects ofRespiratory Diseases and the project of improving clinical skills of majordiseases in Shanghai as well.
Inclinical work, Dr. He diagnoses and treats more than 2000 patients every year,including 600 newly diagnosed lung cancer patients, more than 300 cases ofpulmonary puncture and 200 cases of tracheoscopy were completed every year byher. In clinical work, the researches on lung cancer transformation have beencarried out. The results have been orally exchanged and displayed in wallnewspapers at international conferences such as ASCO, ESMO and WCLC, and Dr. Heobtained ESMO Travel Grant in 2016. Dr. He participates in a number of targetedlung cancer treatment, immunotherapy and other related multi-center, phase IIIclinical researches. At present, 39 papers have been published in all and 25papers have been published as the first author, covering molecular targetedtherapy, immunotherapy and early diagnosis of lung cancer. As a secretary, sheparticipated in the preparation of the guidelines for the diagnosis andtreatment of CSCO primary lung cancer in 2019 and the consensus of Chineseexperts on anti-angiogenesis drugs for advanced non-small cell lung cancer. Sixnational utility model patents have been applied for as the first inventor.